Insider Transactions in Q1 2025 at Med Tech Acquisition Corp (MTACW)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
James Emmett Young Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,762
+28.8%
|
-
|
|
Feb 18
2025
|
Sean Murphy Chief Manuf, Strategy&Bus Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
15,817
+16.66%
|
-
|
|
Feb 18
2025
|
Bryan F. Cox CHIEF OF RESEARCH |
BUY
Grant, award, or other acquisition
|
Direct |
11,450
+9.55%
|
-
|
|
Feb 18
2025
|
Jennifer Stevens CHIEF REGULATORY OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,481
+20.01%
|
-
|
|
Feb 18
2025
|
Mary T Szela CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
21,089
+4.34%
|
-
|
|
Feb 18
2025
|
Richard Marshak Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,644
+12.35%
|
-
|
|
Feb 18
2025
|
Jodi Devlin Chief of Clinical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,272
+13.63%
|
-
|
|
Feb 05
2025
|
James Emmett Young Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
6,000
+16.67%
|
$30,000
$5.65 P/Share
|
|
Jan 30
2025
|
Mary T Szela CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
5,010
+1.12%
|
$25,050
$5.28 P/Share
|
|
Jan 29
2025
|
Mary T Szela CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
5,030
+1.13%
|
$25,150
$5.03 P/Share
|
|
Jan 28
2025
|
Mary T Szela CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
4,716
+1.07%
|
$23,580
$5.12 P/Share
|
|
Jan 28
2025
|
Sean Murphy Chief Manuf, Strategy&Bus Dev. |
BUY
Open market or private purchase
|
Indirect |
15,000
+7.05%
|
$75,000
$5.17 P/Share
|
|
Jan 27
2025
|
Mary T Szela CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
4,826
+1.11%
|
$24,130
$5.42 P/Share
|
|
Jan 27
2025
|
Mary T Szela CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+8.61%
|
-
|
|
Jan 27
2025
|
Sean Murphy Chief Manuf, Strategy&Bus Dev. |
BUY
Open market or private purchase
|
Indirect |
15,000
+7.59%
|
$75,000
$5.31 P/Share
|
|
Jan 27
2025
|
Sean Murphy Chief Manuf, Strategy&Bus Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+16.49%
|
-
|
|
Jan 27
2025
|
Bryan F. Cox CHIEF OF RESEARCH |
BUY
Grant, award, or other acquisition
|
Direct |
10,625
+9.87%
|
-
|
|
Jan 27
2025
|
Jodi Devlin Chief of Clinical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
10,625
+27.42%
|
-
|
|
Jan 27
2025
|
James Emmett Young Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
24,000
+50.0%
|
$120,000
$5.4 P/Share
|
|
Jan 27
2025
|
James Emmett Young Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+36.52%
|
-
|
|
Jan 27
2025
|
Jennifer Stevens CHIEF REGULATORY OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,625
+19.66%
|
-
|
|
Jan 27
2025
|
Richard Marshak Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+21.14%
|
-
|
|
Jan 02
2025
|
David J Matlin |
BUY
Grant, award, or other acquisition
|
Direct |
10,040
+1.05%
|
-
|
|
Jan 02
2025
|
Liselotte Hyveled |
BUY
Grant, award, or other acquisition
|
Direct |
10,040
+50.0%
|
-
|